Cargando…

(68)Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients

BACKGROUND: To report on imaging findings using (68)Ga-PSMA-HBED-CC PET in a series of 19 breast carcinoma patients. METHODS: (68)Ga-PSMA-HBED-CC PET imaging results obtained were compared to routinely performed staging examinations and analyzed as to lesion location and progesterone receptor status...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sathekge, Mike, Lengana, Thabo, Modiselle, Moshe, Vorster, Mariza, Zeevaart, JanRijn, Maes, Alex, Ebenhan, Thomas, Van de Wiele, Christophe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323468/ https://www.ncbi.nlm.nih.gov/pubmed/27822700 http://dx.doi.org/10.1007/s00259-016-3563-6

Ejemplares similares

(68)Ga-PSMA-11 PET/CT in primary staging of prostate carcinoma: preliminary results on differences between black and white South-Africans
por: Sathekge, Mike, et al.
Publicado: (2017)

Development of a Single Vial Kit Solution for Radiolabeling of (68)Ga-DKFZ-PSMA-11 and Its Performance in Prostate Cancer Patients
por: Ebenhan, Thomas, et al.
Publicado: (2015)

Repeatability of (68)Ga-PSMA-HBED-CC PET/CT–Derived Total Molecular Tumor Volume
por: Seifert, Robert, et al.
Publicado: (2022)

PSMA Theranostics: Science and Practice
por: Mokoala, Kgomotso, et al.
Publicado: (2021)

Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
por: Dietlein, Markus, et al.
Publicado: (2015)

Preclinical Assessment Addressing Intravenous Administration of a [(68)Ga]Ga-PSMA-617 Microemulsion: Acute In Vivo Toxicity, Tolerability, PET Imaging, and Biodistribution
por: Mandiwana, Vusani, et al.
Publicado: (2021)

Novel Preclinical and Radiopharmaceutical Aspects of [(68)Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer
por: Eder, Matthias, et al.
Publicado: (2014)

(213)Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
por: Sathekge, Mike, et al.
Publicado: (2017)

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2014)

(68)Ga-PSMA-11 PET/CT Initial Staging in Black and White South African Males with ISUP Grade Group 1 and 2 Prostate Adenocarcinoma
por: Maserumule, Letjie C., et al.
Publicado: (2022)

Pattern of Prostate Cancer Recurrence Assessed by (68)Ga-PSMA-11 PET/CT in Men Treated with Primary Local Therapy
por: Lawal, Ismaheel O., et al.
Publicado: (2021)

(68)Ga-HBED-CC-PSMA PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison
por: Zamboglou, Constantinos, et al.
Publicado: (2016)

Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
por: Afshar-Oromieh, Ali, et al.
Publicado: (2017)

Preclinical Assessment of a (68)Ga-DOTA-Functionalized Depsipeptide as a Radiodiagnostic Infection Imaging Agent
por: Ebenhan, Thomas, et al.
Publicado: (2017)

Potential of asphericity as a novel diagnostic parameter in the evaluation of patients with (68)Ga-PSMA-HBED-CC PET-positive prostate cancer lesions
por: Meißner, Sebastian, et al.
Publicado: (2017)

Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer
por: Jilg, Cordula A., et al.
Publicado: (2017)

Uptake in non-affected bone tissue does not differ between [(18)F]-DCFPyL and [(68)Ga]-HBED-CC PSMA PET/CT
por: Hammes, Jochen, et al.
Publicado: (2018)

(68)Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study
por: van Boxtel, Wim, et al.
Publicado: (2020)

(68)Ga-HBED-CC-WL-12 PET in Diagnosing and Differentiating Pancreatic Cancers in Murine Models
por: Xiang, Qiying, et al.
Publicado: (2023)

(68)Ga‐nitroimidazole PET/CT imaging of hypoxia in tuberculosis: A case series
por: Bresser, Philippa L, et al.
Publicado: (2022)

Focal dose escalation for prostate cancer using (68)Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference
por: Zamboglou, Constantinos, et al.
Publicado: (2018)

(225)Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
por: Sathekge, Mike, et al.
Publicado: (2018)

PSMA PET/CT with Glu-urea-Lys-(Ahx)-[(68)Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer
por: Giesel, Frederik L., et al.
Publicado: (2015)

68Ga-PSMA-HBED-CC PET/MRI is superior to multiparametric magnetic resonance imaging in men with biochemical recurrent prostate cancer: A prospective single-institutional study
por: Martinez, Juana, et al.
Publicado: (2021)

Current Status of (68)Ga-Pentixafor in Solid Tumours
por: Hadebe, Bawinile, et al.
Publicado: (2022)

Diagnostic value of sentinel lymph node scintigraphy and 2-[(18)F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the detection of metastatic lymph nodes in patients with early-stage cervical cancer
por: Reyneke, Florette, et al.
Publicado: (2020)

Towards Facile Radiolabeling and Preparation of Gallium-68-/Bismuth-213-DOTA-[Thi(8), Met(O(2))(11)]-Substance P for Future Clinical Application: First Experiences
por: Suthiram, Janine, et al.
Publicado: (2021)

Comparison of (68)Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology
por: Zamboglou, Constantinos, et al.
Publicado: (2017)

Can Early Dynamic Positron Emission Tomography/Computed Tomography Obviate the Need for Postdiuresis Image in (68)Ga-PSMA-HBED-CC Scan for Evaluation of Prostate Adenocarcinoma?
por: Perveen, Gazala, et al.
Publicado: (2018)

Correlation between [(68)Ga]Ga-FAPI-46 PET Imaging and HIF-1α Immunohistochemical Analysis in Cervical Cancer: Proof-of-Concept
por: Mokoala, Kgomotso M. G., et al.
Publicado: (2023)

Ga-68 Prostate-Specific Membrane Antigen-HBED-CC Positron Emission Tomography/Computed Tomography in Anaplastic Thyroid Carcinoma
por: Subudhi, T. Kishan, et al.
Publicado: (2022)

Incidental Detection of Asymptomatic Brain Metastases Due to Carcinoma Prostate in Ga-68 PSMA HBED-CC Positron Emission Tomography-Computed Tomography: Reiterating its Superiority in Assessing Disease Status
por: Nellaiappan, Harihara Sudhan, et al.
Publicado: (2022)

Global experience with PSMA-based alpha therapy in prostate cancer
por: Sathekge, Mike M., et al.
Publicado: (2021)

Synthesis, (68)Ga-Radiolabeling, and Preliminary In Vivo Assessment of a Depsipeptide-Derived Compound as a Potential PET/CT Infection Imaging Agent
por: Mokaleng, Botshelo B., et al.
Publicado: (2015)

Antimicrobial Peptides: Their Role as Infection-Selective Tracers for Molecular Imaging
por: Ebenhan, Thomas, et al.
Publicado: (2014)

A Prospective Investigation of Tumor Hypoxia Imaging with (68)Ga-Nitroimidazole PET/CT in Patients with Carcinoma of the Cervix Uteri and Comparison with (18)F-FDG PET/CT: Correlation with Immunohistochemistry
por: Mokoala, Kgomotso M. G., et al.
Publicado: (2022)

Synthesis of an Al(18)F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand in an automated synthesis platform
por: Giglio, Javier, et al.
Publicado: (2018)

(225)Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings
por: Sathekge, Mike, et al.
Publicado: (2023)

Musculoskeletal pitfalls in (68)Ga-PSMA PET/CT
por: Pontes, Írline Cordeiro de Macedo, et al.
Publicado: (2023)

Role of Early Dynamic Positron Emission Tomography/Computed Tomography with 68Ga-prostate-specific Membrane Antigen-HBED-CC in Patients with Adenocarcinoma Prostate: Initial Results
por: Perveen, Gazala, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sckn1gqkie7uol1o969565ub76